Chromatics Color Sciences International. Inc; CCSI Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Chromatics Color Sciences International. Inc; CCSI

CCSI 29.77

+3.7%

Nov 5 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Gurupup who wrote (1618)	3/31/1998 4:12:00 PM
From: JanyBlueEyes	Read Replies (2) of 5736

NEWS - New Medical Application in Dermatology Company Announces Completion of Studies for New Medical Application in Dermatology NEW YORK--(BUSINESS WIRE)--March 31, 1998--Chromatics Color Sciences, International Inc.(NASDAQ:CCSI - news) announced today that it has completed feasibility studies pending IRB approval to commence clinical trials of the Company's Colormate(TM) device with Dr. Mark Lebwohl, Professor and Chairman, Department of Dermatology at Mt. Sinai Hospital in New York City for use in determining the level of phototherapy treatment to be used in treating numerous skin disorders and diseases and the patient's tolerance to such phototherapy treatment by quantifying the amount of pigmentation and hence, photo-protection in the skin of patients. This dermatological application of the Company's proprietary technology and device would be for patients of all ages and would be used in determining dosages of ultraviolet light (phototherapy treatment) to treat patients for a variety of diseases including psoriasis, eczema, cutaneous T-cell lymphoma, vitiligo, and others. Post inflammatory hyperpigmentation would also be a condition subject to monitoring by the noninvasive technology of the Colormate device. The noninvasive measurement of the skin color by the Company's Colormate device will be tested and verified against minimal erythema dose-testing including the Fitzpatrick skin type test. This use of the Colormate device most likely will require additional FDA clearance through submission of a marketing application supported by clinical data. The Company is engaged in the business of color science and has developed technologies and intellectual properties which the Company believes have medical applications involving the detection and monitoring of certain chromogenic diseases or disorders such as bilirubin infant jaundice. In this regard, the Company has received FDA clearance for commercial marketing of the Company's medical device for detection and monitoring of bilirubin infant jaundice. Other medical applications will most likely require additional clinical trials and FDA clearance. The Company defines chromogenic disease or disorders as those diagnosed or monitored by the coloration of the human skin, tissue or fluid being affected. These technologies and intellectual properties also have other applications including the scientific color measurement and classification of human skin, certain color-sensitive consumer products, and in determining the color compatibility of such skin and product color classification for use in a variety of industries including the cosmetic, beauty aid and fashion industries. The Company's common stock is traded on NASDAQ under the symbol ''CCSI''. Certain of the matters discussed in this announcement contain forward-looking statements.......

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next